Key Takeaways
- Novo Nordisk (NVO) reported a significant miss across key financial metrics for Q3 2025, with revenue of DKK 74.98 billion and net income of DKK 20.01 billion both falling short of analyst expectations.
- BMW (BMW.DE) delivered a mixed Q3 2025 performance, as revenue of €32.3 billion missed estimates, but net profit climbed to €1.7 billion and Automotive EBIT Margin reached 5.2%, both surpassing expectations.
- Despite the mixed results, BMW (BMW.DE) reaffirmed its full-year outlook, confirming its adjusted targets and maintaining its Automotive EBIT Margin forecast of 5%–6%.
Novo Nordisk's Q3 Falls Short Across Key Metrics
Pharmaceutical giant Novo Nordisk (NVO) experienced a challenging third quarter, with its earnings report revealing misses across several critical financial indicators. The company reported revenue of DKK 74.98 billion, falling below the estimated DKK 76.68 billion. Similarly, net income for the quarter stood at DKK 20.01 billion, missing the DKK 20.82 billion estimate.
Further indicating a softer performance, EBIT came in at DKK 23.68 billion against an estimated DKK 25.61 billion, and pretax profit was DKK 25.52 billion compared to an estimated DKK 26.42 billion. The company's gross margin also saw a decline, reaching 76.1% against an estimated 81.1%. While specific estimates for Wegovy sales were not fully disclosed, the reported DKK 20.35 billion in sales for the popular weight-loss drug was noted.
BMW Navigates Mixed Q3 with Profit Beat
BMW (BMW.DE) presented a more nuanced picture for its Q3 2025 earnings, with some key metrics exceeding expectations despite a revenue miss. The luxury automaker reported revenue of €32.3 billion, which was below the consensus estimate of €33.8 billion. Automotive revenue specifically came in at €28.51 billion, slightly missing the €28.77 billion estimate.
However, the company showcased strong profitability, with Group EBIT matching estimates at €2.26 billion. Notably, BMW's net profit soared to €1.7 billion, significantly beating the estimated €1.5 billion. The Automotive EBIT Margin also impressed, reaching 5.2% and surpassing the 4.9% estimate.
Full-Year Outlook Confirmed Amidst R&D Focus
Despite the mixed Q3 results, BMW (BMW.DE) confirmed its adjusted full-year targets, which were initially announced in October. The company reiterated its forecast for the full-year Automotive EBIT Margin to remain within the 5%–6% range. This reaffirmation signals management's confidence in achieving its strategic objectives for the remainder of the year, even as it continues to invest in R&D and Capex.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.